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Abstract:Myoﬁbroblasts produce the ﬁbrous scar in hepatic ﬁbrosis.
In the carbon tetrachloride (CCl(4)) model of liver ﬁbrosis, quiescent
hepatic stellate cells (HSC) are activated to become myoﬁbroblasts.
When the underlying etiological agent is removed, clinical and exper-
imental ﬁbrosis undergoes a remarkable regression with complete
disappearance of these myoﬁbroblasts. Although some myoﬁbro-
blasts apoptose, it is unknown whether other myoﬁbroblasts may
revert to an inactive phenotype during regression of ﬁbrosis. We elu-
cidated the fate of HSCs/myoﬁbroblasts during recovery from CCl(4)-
and alcohol-induced liver ﬁbrosis using Cre-LoxP-based genetic
labeling of myoﬁbroblasts. Here we demonstrate that half of the
myoﬁbroblasts escape apoptosis during regression of liver ﬁbrosis,
down-regulate ﬁbrogenic genes, and acquire a phenotype similar
to, but distinct from, quiescent HSCs in their ability to more rapidly
reactivate into myoﬁbroblasts in response to ﬁbrogenic stimuli and
strongly contribute to liver ﬁbrosis. Inactivation of HSCs was associ-
ated with up-regulation of the anti-apoptotic genes Hspa1a/b, which
participate in the survival of HSCs in culture and in vivo.
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(HSCs), the main ﬁbrogenic cell type in the liver, undergo apoptosis
after cessation of liver injury, which contributes to resolution of
ﬁbrosis. In this study, we investigated whether HSC deactivation
constitutes an additional mechanism of liver ﬁbrosis resolution.
Methods: HSC activation and deactivation were investigated by sin-
gle-cell PCR and genetic tracking in transgenic mice that expressed a
tamoxifen-inducible CreER under control of the endogenous vimentin
promoter (Vimentin-CreER).
Results: Single-cell quantitative polymerase chain reaction demon-
strated activation of almost the entire HSC population in ﬁbrotic liv-
ers, and a gradual decrease of HSC activation during ﬁbrosis
resolution, indicating deactivation of HSCs. Vimentin-CreER marked
activated HSCs, demonstrated by a 6- to 16-fold induction of a mem-
brane-bound green ﬂuorescent protein (mGFP) Cre-reporter after
injection of carbon tetrachloride, in liver and isolated HSCs, and a
shift in localization of mGFP-marked HSCs from peri-sinusoidal to
ﬁbrotic septa. Tracking of mGFP-positive HSCs revealed the persis-
tence of 40%-45% of mGFP expression in livers and isolated HSCs
30-45 days after carbon tetrachloride was no longer administered,
despite normalization of ﬁbrogenesis parameters; these ﬁndings con-
ﬁrm reversal of HSC activation. After ﬁbrosis resolution, mGFP
expression was observed again in desmin-positive peri-sinusoidal
HSCs; no mGFP expression was detected in hepatocytes or cholangio-
cytes, excluding mesenchymal-epithelial transition. Notably,
reverted HSCs remained in a primed state, with higher levels of
responsiveness to ﬁbrogenic stimuli.
Conclusions: In mice, reversal of HSC activation contributes to termi-
nation of ﬁbrogenesis during ﬁbrosis resolution, but results in higher
responsiveness of reverted HSCs to recurring ﬁbrogenic stimulation.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
Activation of hepatic stellate cells (HSC) in response to chronic
liver injury is a key step in the pathogenesis of liver ﬁbrosis. The
activation process is characterized by a phenotypic switch from
a quiescent vitamin A-rich to a myoﬁbroblastic ﬁbrogenic pheno-
type [1] (Fig. 1). Fibrosis has long been viewed as an irreversible
process, but convincing clinical and experimental studies have
demonstrated that ﬁbrosis resolution may occur upon eradication
of the liver insult [2]. Experimental models of ﬁbrosis recovery
consistently reported that elimination of activated HSC by apop-
tosis [3] or senescence [4] precedes restoration of ﬁbrolytic path-
ways and regression of ﬁbrosis, suggesting that clearance of
activated HSC is a key step in the onset of ﬁbrosis regression.
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Fig. 1. Fate of hepatic stellate cells during liver ﬁbrosis progression and resolution. Upon liver injury, HSCs undergo transdifferentiation from a quiescent to a
myoﬁbroblastic phenotype. The process is orchestrated by interactions with neighboring parenchymal and non-parenchymal cells (immune cells, capillarized liver
sinusoidal endothelial cells), and by cell matrix components, interactions mediated through integrins, and matrix stiffness. Activated HSCs are characterized by enhanced
capacity to proliferate and produce proinﬂammatory and proﬁbrogenic mediators and are responsible for secreting extracellular matrix that characterizes liver ﬁbrosis.
Clearance of activated HSC is a key step in ﬁbrosis regression, and may result from apoptosis, promoted by NK cells, dendritic cells, and proresolution macrophages, or from
reversion to a quiescent phenotype. The studies of Troeger and Kisseleva demonstrate signiﬁcant reversion/inactivation of myoﬁbroblastic HSC in animals undergoing
ﬁbrosis recovery. However, deactivated HSC do not fully revert to a quiescent state, but retain a preactivated intermediate state and show enhanced susceptibility to
subsequent insult.
International HepatologyAlthough culture studies suggested that disappearance of acti-
vated HSCmay also result from reversal to a quiescent phenotype,
whether deactivation may occur in vivo during ﬁbrosis regression
remained unsolved. In two recent reports, Kisseleva et al. [5] and
Troeger et al. [6] elegantly address this issue, using a combination
of genetic cell fate tracking approach [5,6], single cell PCR [6], and
microarray analysis [5,6].384 Journal of Hepatology 201Both groups used mouse models in which quiescent and
activated HSC can be permanently stamped and tracked with
a ﬂuorescent label at the onset of ﬁbrosis and during resolution.
Kisseleva et al. [5] generated a type I collagen promoter-driven
Cre-mediated removal of a STOP cassette in a reporter (YFP)
mouse strain. Because only activated hepatic myoﬁbroblasts
express collagen I, they can be identiﬁed by YFP labeling. Liver3 vol. 59 j 383–386
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ﬁbrosis was induced by chronic carbon tetrachloride adminis-
tration or intragastric alcohol feeding in Cola1(1)Cre-YFP or
Cola2(1)Cre-YFP mice, and the fate of YFP-labeled HSC was fol-
lowed in mice that were allowed to recover for 4–7 weeks. As
previously reported, recovery was associated with a marked
decrease in the density of a-smooth muscle actin (a-SMA)-posi-
tive cells and a parallel normalization of ﬁbrosis parameters.
More surprisingly, few apoptotic YFP positive cells were
detected (2.6%) whereas hepatic YFP labeling persisted in 50%
of cells expressing vitamin A. The low rate of apoptosis com-
pared to previous studies [3] might be due to the ephemeral
nature of apoptosis, but nevertheless, these ﬁndings argue for
the reversion of a signiﬁcant number of myoﬁbroblastic HSC
to a quiescent state during the recovery phase. Similar ﬁndings
were obtained by Troeger et al [6]. They followed the fate of
activated hepatic stellate cells using a bacterial artiﬁcial chro-
mososme transgenic mice expressing a tamoxifen-inducible
CreER driven by the endogenous promoter for vimentin (an
intermediate ﬁlament protein highly expressed in myoﬁbro-
blasts), that were crossed to a ﬂuorescent (mGFP) mouse repor-
ter mice. Activated HSC were tracked in mice exposed to carbon
tetrachloride, thioacetamide or bile duct ligation during ﬁbrosis
progression and recovery. In addition, FACS sorting and single
cell PCR analysis of mGFP labeled cells, isolated at various times
after cessation of injury, indicated that the expression of charac-
teristic ﬁbrogenic markers of activated HSC (collagen I, TIMP1,
a-SMA, TGF-bR) gradually decreases over time during the recov-
ery period.
Intriguingly, comparative gene analysis showed that although
reverted HSC reacquire several features of quiescence, they also
display speciﬁc characteristics with respect to quiescent stellate
cells that had never been exposed to a ﬁbrogenic stimulus.
Reverted HSC in culture displayed enhanced susceptibility to sub-
sequent activation by TGF-b1 or mitogens [5,6]. These data indi-
cated that reverted HSC do not fully revert to a quiescent state,
but rather retain a preactivated intermediate state (Fig. 1). Inter-
estingly, administration of a second round of carbon tetrachloride
after a 6-month recovery period induced more severe ﬁbrosis,
compared to mice that received one round of the hepatotoxin,
suggesting that reverted HSC may account for more rapid and
more severe ﬁbrosis progression upon recurrence of liver injury.
Characterization of the mechanisms that maintain HSC in an
‘‘intermediate’’ phenotype is required to fully understand why
activated HSC only partially deactivate upon cessation of the
insult, but this issue was not addressed in either study. In this
respect, whether irreversible changes in the hepatic microenvi-
ronment within the injured liver underlie partial phenotype
reversion needs to be considered. Indeed, matrix stiffness, cell
matrix components such as collagen 1 and integrins, are known
to drive and maintain HSC in the activated state [1,7], and it
has been reported that irreversible collagen cross-linking persists
even after long-term recovery from ﬁbrosis [8] (Fig. 1). In addi-
tion, the role of neighboring cells also warrants further investiga-
tion, in particular the liver sinusoidal endothelial cells, which
control HSC activation/deactivation [9].
Altogether, the ﬁndings of Kisseleva and Troeger broaden
our current view of ﬁbrogenic cell heterogeneity based on their
diverse origin, including HSC, portal myoﬁbroblasts, bone mar-
row-derived ﬁbroblasts and ﬁbrocytes. Indeed, these studies
identify hepatic stellate cells as a plastic population that can
adopt a wide range of phenotypes, ranging from a fullyJournal of Hepatology 201quiescent to an activated myoﬁbroblastic state, as described
for myeloid cells. Nevertheless, a number of issues remain unre-
solved. In particular, whether the inactivation process is speciﬁc
to HSC or also affects other liver ﬁbrogenic cells remains to be
determined. This is an important point, given the predominant
role of speciﬁc liver ﬁbrogenic cell populations according to the
cause of liver injury, as illustrated by the major contribution of
portal myoﬁbroblasts to biliary cirrhosis [10]. Another major
question relates to the characterization of the mechanisms reg-
ulating elimination of activated HSC by apoptosis or phenotype
reversion, and the functional consequences of the two pathways
on ﬁbrosis resolution. In this respect, the study of Kisseleva
et al. [5] suggests that anti-apoptotic signals such as HSPa1a/b
are speciﬁcally expressed by HSC undergoing inactivation and
participate in the survival of HSCs in culture and in vivo.
Although Troger et al. did not conﬁrm these ﬁndings [6], these
data suggest that the balance between pro and anti-apoptotic
proteins may represent one of the key mechanisms that govern
the fate of activated HSC. Finally, determining whether the
reverted phenotype represents an ultimate state or if inacti-
vated cells can further evolve towards a quiescent phenotype
will also be a critical issue to be addressed.
These two convergent studies provide compelling experimen-
tal evidence supporting in vivo HSC reversion during ﬁbrosis
recovery (Fig. 1). The question as to the causal relationship
between HSC reversion and ﬁbrosis resolution still remains open
as well as to the respective roles of apoptotic vs. reverted HSCs in
the recovery process. Determination of the clinical relevance of
the current ﬁndings is another major issue that might prove chal-
lenging, given the current lack of assays available for HSC fate
tracking in humans.Financial support
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